Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY® by the National Medical Products Administration of China for the Treatment of Moderately to Severely Active Ulcerative Colitis
SHANGHAI, Dec. 17, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the National Medical Products Administration (NMPA) of China has officially accepted the New Drug Application (NDA) for VELSIPITY® (etrasimod) for the treatment of patients with moderately to severely...
Amai Proteins succesfully completed world’s first human clinical trial on effects of sweet proteins, with sweelin®
REHOVOT, Israel, Dec. 17, 2024 /PRNewswire/ -- Amai Proteins, a scale-up designer of novel proteins that answer the needs of consumers and industry, has succesfullly completed world's first double-blind, random clinical trial on the effects of their proprietary hyper-sweet protein, sweelin®, on blood glucose and insulin levels in humans. ...
SK Biopharmaceuticals Inks Research Collaboration Agreement with ProEn Therapeutics Further Accelerating Expansion of Oncology Research and Pipeline for Global Competitiveness in Radiopharmaceuticals
SK Biopharmaceuticals, ProEn Therapeutics aim to advance up to 2 preclinical radiopharmaceutical candidates by 2027, via ArtBody™, a bivalent binder platform designed to selectively target tumor cells SK Biopharmaceuticals eyes innovative small protein-based radiopharmaceuticals on safety and efficacy amid growing global demand through the joint research initiative building on the momentum for its radiopharmaceutical therapy business SEOUL, South Korea,...
Samsung Biologics listed among top most sustainable companies in Dow Jones Sustainability World Index
Acknowledged for strong environmental, social, and governance (ESG) performance and continued commitment to sustainability through net-zero initiatives and responsible value chain management INCHEON, South Korea, Dec. 17, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced its continued recognition by the Dow...
Microbio Co., Ltd. (4128) Announces Promising Results of “MS-20” in Combination with Keytruda for Stage IIIb/IV Non-Small Cell Lung Cancer
CUPERTINO, Calif., Dec. 17, 2024 /PRNewswire/ -- Microbio Co., Ltd. (4128) today revealed encouraging results from an exploratory clinical trial of MS-20 combined with Keytruda (pembrolizumab) in stage IIIb/IV non-small cell lung cancer (NSCLC). The trial showed a threefold increase in the objective response rate (ORR) for the MS-20-Keytruda group (75%) compared to Keytruda alone (25%). Additionally, the...
Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg
– Both pivotal studies achieved primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies with high statistical significance (p<0.0001) – Approximately 50% of patients in BROADWAY (Obicetrapib monotherapy) and over 70% of patients in TANDEM (Fixed Dose Combination Obicetrapib with Ezetimibe) achieved LDL-C target below 55 mg/dL ...
World’s 1st Stem Cell Book on Animals, Reveals How to Extend the Lives of Pets
KOTA KINABALU, Malaysia, Dec. 16, 2024 /PRNewswire/ -- A groundbreaking new book by Professor Dr. Mike Chan, "STEM CELLS, PEPTIDES & IMMUNOTHERAPY: Handbook on Regenerative Medicine for Animals," introduces revolutionary stem cell therapies that promise to extend the health span and longevity of horses, camels, dogs, and cats. Regenerative Medicine for Animals:...
Everise Expands and Diversifies Its Healthcare Services Portfolio With the Acquisition of Continuum Global Solutions’ Vertical
The acquisition strengthens Everise's position as a leading end-to-end healthcare experience provider PLANTATION, Fla., Dec. 16, 2024 /PRNewswire/ -- Everise, a global healthcare customer experience leader, today announced the successful completion of its acquisition of customer experience management company Continuum Global Solutions' (CGS) healthcare and utilities verticals from Skyview Capital. This milestone...
Nona Biosciences Announces Discovery Collaboration with Candid Therapeutics for Next-Generation T-Cell Engagers
CAMBRIDGE, Mass., Dec. 16, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), today announced a research collaboration and license agreement to discover next-generation T-cell engagers ("TCEs") with Candid Therapeutics, Inc. ("Candid"), a clinical-stage biotechnology company based in San Diego and focused on...
Perennial General Hospital Tianjin, China’s First Wholly Foreign-Owned Private Tertiary General Hospital Will Soon Commence Operations
SINGAPORE, Dec. 16, 2024 /PRNewswire/ -- Perennial Holdings Private Limited ("Perennial Holdings") is pleased to announce that Perennial General Hospital in Tianjin city ("Perennial General Hospital Tianjin"), China, has become the country's first wholly foreign-owned private tertiary general hospital after it successfully passed the city's Municipal Health Commission's stringent hospital inspection and obtained...
